<DistDoc action="rep" dist="dist_id" distdocver="05.1" an="WSJO000020180322ee3m000b5" doctype="article"><SelectData><FolderName id="302210898" rl="100">FNA US/Europe Economics</FolderName><FolderName id="302210958" rl="100">WSJ</FolderName></SelectData><ReplyItem lang="en"><BaseLang value="en" fid="la"/><IPDocId fid="id">39F07E1B4A780FC280C95C75088DFDF2 SB12695538546930973963904584115800976799312</IPDocId><AccessionNo value="WSJO000020180322ee3m000b5" fid="an"/><Num value="652" fid="wc"/><Date value="20180322" fid="pd"/><Time value="022400" fid="et"/><SrcCode value="wsjo" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><TruncRules><XS value="28"/><S value="60"/><M value="75"/><L value="135"/></TruncRules><Title fid="hl"><SectionName fid="se">Politics</SectionName><ColumnName fid="clm"></ColumnName><Headline fid="hd"><Para lang="en">House Passes Bill Giving the Terminally Ill Easier Access to Unproven Drugs; Legislation changed a version passed by Senate, seeking to address criticism by some medical groups</Para></Headline></Title><Snippet><Para>The House of Representatives passed a "Right to Try" bill backed by the White House that would make unproven drugs more easily available to terminally ill patients, following changes made to address criticism of a version passed by the ...</Para></Snippet><Byline fid="by">By Thomas M. Burton </Byline><Credit fid="cr"></Credit><Copyright fid="cy">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright><CodeSets><CSet fid="co"><Code value="usfda"/></CSet><CSet fid="in"><Code value="i257"/><Code value="i951"/></CSet><CSet fid="re"><Code value="namz"/><Code value="usa"/></CSet><CSet fid="ns"><Code value="gpol"/><Code value="gvuph"/><Code value="gvlwh"/><Code value="gcat"/><Code value="ghea"/><Code value="gpir"/><Code value="gvbod"/><Code value="gvcng"/></CSet></CodeSets></ReplyItem><MetadataPT><DocData><DocType value="article" fid="fmt"/><IPDocId fid="id">39F07E1B4A780FC280C95C75088DFDF2 SB12695538546930973963904584115800976799312</IPDocId><AccessionNo value="WSJO000020180322ee3m000b5" fid="an"/><Num value="652" fid="wc"/><Num value="3371" fid="cc"/><Date value="20180322" fid="pd"/><Date value="20180322" fid="upd"/><Date value="20180322" fid="md"/><Time value="022400" fid="et"/><Time value="022448" fid="upt"/><Time value="063235" fid="mt"/><BaseLang value="en" fid="la"/><Editor value="" fid="rve"/><RevisionNo value="2" fid="rvn"/></DocData><PubData><Restrictor fid="rst"><Code value="FSPNORMAWS0300"/><Code value="WSJO"/><Code value="fspFileId275395796"/><Code value="FUT"/><Code value="CLNTALL"/><Code value="CTGSMFS"/><Code value="CTGWSJ"/><Code value="DEEPWSJP"/><Code value="EN"/><Code value="IBNK"/><Code value="IFINAL"/><Code value="IINV"/><Code value="NAMZ"/><Code value="SFWSJ"/><Code value="TBAC"/><Code value="TBED"/><Code value="TBIZ"/><Code value="TBRK"/><Code value="TDJP"/><Code value="TDJWMNP"/><Code value="TFCDLIC"/><Code value="TFIN"/><Code value="TIAS"/><Code value="TIBMNB"/><Code value="TIMG"/><Code value="TINT"/><Code value="TIOP"/><Code value="TMNB"/><Code value="TMNBUS"/><Code value="TNPS"/><Code value="TNWP"/><Code value="TNWPN"/><Code value="TOPUSA"/><Code value="TSCH"/><Code value="TTRD"/><Code value="TTRK"/><Code value="TUSN"/><Code value="TWMSA"/><Code value="TYAS"/><Code value="TYLA"/><Code value="USA"/><Code value="fspWebpage"/><Code value="MPCV1M9M1B1"/><Code value="MPCEnvPROD"/><Code value="MPCDocHash0163DA1819956E80"/><Code value="FSP2YESCOOC"/><Code value="FSP2YESCOORGOC"/><Code value="FSPRBC"/><Code value="FSPRBCCO"/><Code value="FSPRBCORG"/><Code value="FSP2YESCO"/><Code value="FSP2YESCOORG"/><Code value="FSPRBCIN"/><Code value="FSP2YESIN"/><Code value="FSPCATEGORIZER"/><Code value="FSPCATNS"/><Code value="FSPRBCNS"/><Code value="FSP2YESNS"/><Code value="FSPRBCRE"/><Code value="FSP2YESRE"/><Code value="FSP2YESPEOC"/><Code value="FSPRBC579860"/><Code value="FSPRBC697573"/><Code value="FSPRBC698693"/><Code value="FSPRBC799599"/><Code value="FSPRBC799842"/><Code value="FSPRBC800731"/><Code value="FSPRBC801038"/><Code value="FSPRBC802123"/><Code value="FSPRBC803821"/><Code value="FSPRBC830855"/><Code value="FSPRBC831127"/><Code value="FSPRBC831151"/><Code value="FSPRBC849276"/><Code value="FSPRBC849536"/><Code value="FSPRBC849559"/><Code value="FSPRBC857690"/><Code value="FSPRBC857691"/><Code value="FSPRBC860177"/><Code value="FSPRBC860298"/><Code value="FSPRBC860312"/><Code value="FSPRBC860380"/><Code value="FSPRBC861461"/><Code value="FSPRBC861689"/><Code value="FSPRBC861918"/><Code value="MPCCL"/><Code value="MPCJP"/><Code value="MPCKW"/><Code value="MPCKP"/><Code value="MPCESRE"/><Code value="MPCESIN"/><Code value="MPCESNS"/><Code value="FSP2AC"/></Restrictor><IPId value="DJENT" fid="ip"/><PublisherN fid="pub">Dow Jones &amp; Company, Inc.</PublisherN><AttribCode value="WSJO2" fid="atr"/><SrcCode value="WSJO" fid="sc"/><SrcName fid="sn">The Wall Street Journal Online</SrcName><Logo img="wsjoLogo.gif" link="" src="http://logos.factiva.com"/></PubData><CodeSets><CSet fid="co"><Code value="usfda"><CodeD index="no" lang="en">U.S. Food and Drug Administration</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="698693"/><CodeA name="db" value="prbc---00018570-20180321-194323"/><CodeA name="rule" value="579860"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI></Code></CSet><CSet fid="in"><Code value="i257"><CodeD index="no" lang="en">Pharmaceuticals</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="802123"/><CodeA name="db" value="prbc---00018570-20180321-194323"/><CodeA name="rule" value="831127"/><CodeA name="rule" value="849536"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="i951"><CodeD index="no" lang="en">Health Care/Life Sciences</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861918"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="in:i257"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code></CSet><CSet fid="re"><Code value="namz"><CodeD index="no" lang="en">North America</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="861461"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="re:usa"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="usa"><CodeD index="no" lang="en">United States</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="698693"/><CodeA name="db" value="prbc---00018570-20180321-194323"/><CodeA name="rule" value="861689"/><CodeA name="rule" value="579860"/><CodeA name="rule" value="697573"/><CodeA name="rule" value="857691"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code></CSet><CSet fid="ns"><Code value="gpol"><CodeD index="no" lang="en">Domestic Politics</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishNS_en_20180316142643"/><CodeA name="es_score" value="218"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="799599"/><CodeA name="db" value="prbc---00018570-20180321-194323"/><CodeA name="rule" value="697573"/><CodeA name="rule" value="857690"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:gvuph"/><CodeA name="root" value="ns:gvlwh"/><CodeA name="root" value="ns:gvbod"/><CodeA name="root" value="ns:gvcng"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="2"/></CodeI></Code><Code value="gvuph"><CodeD index="no" lang="en">Upper House</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishNS_en_20180316142643"/><CodeA name="es_score" value="194"/></CodeI><CodeI org="rbc" action="add"><CodeA name="rule" value="800731"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="5"/></CodeI></Code><Code value="gvlwh"><CodeD index="no" lang="en">Lower House</CodeD><CodeI org="categoriser" action="add"><CodeA name="db" value="es-EnglishNS_en_20180316142643"/><CodeA name="es_score" value="160"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="5"/></CodeI></Code><Code value="gcat"><CodeD index="no" lang="en">Political/General News</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860298"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:gpol"/><CodeA name="root" value="ns:gvuph"/><CodeA name="root" value="ns:gvlwh"/><CodeA name="root" value="ns:ghea"/><CodeA name="root" value="ns:gpir"/><CodeA name="root" value="ns:gvbod"/><CodeA name="root" value="ns:gvcng"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="0"/></CodeI></Code><Code value="ghea"><CodeD index="no" lang="en">Health</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860312"/><CodeA name="db" value="prbc---00018570-20180321-194323"/><CodeA name="rule" value="799842"/><CodeA name="rule" value="803821"/><CodeA name="rule" value="830855"/><CodeA name="rule" value="831151"/><CodeA name="rule" value="849276"/><CodeA name="rule" value="849559"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="gpir"><CodeD index="no" lang="en">Politics/International Relations</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860380"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:gpol"/><CodeA name="root" value="ns:gvuph"/><CodeA name="root" value="ns:gvlwh"/><CodeA name="root" value="ns:gvbod"/><CodeA name="root" value="ns:gvcng"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="1"/></CodeI></Code><Code value="gvbod"><CodeD index="no" lang="en">Government Bodies</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="860177"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:gvuph"/><CodeA name="root" value="ns:gvlwh"/><CodeA name="root" value="ns:gvcng"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="3"/></CodeI></Code><Code value="gvcng"><CodeD index="no" lang="en">Legislative Branch</CodeD><CodeI org="rbc" action="add"><CodeA name="rule" value="801038"/><CodeA name="db" value="prbc---00018570-20180321-194323"/></CodeI><CodeI org="expansion" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="root" value="ns:gvuph"/><CodeA name="root" value="ns:gvlwh"/></CodeI><CodeI org="validation" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="status" value="active"/></CodeI><CodeI org="hierarchy" action="add"><CodeA name="db" value="pedv---00000998-20180321-161406"/><CodeA name="nodelevel" value="4"/></CodeI></Code></CSet></CodeSets><DescTPC fid="de"><DescField fid="ipc">G/FDA G/IGV M/HCR N/GEN N/HLT N/PLT R/NME R/US </DescField><DescField fid="ipd">WSJ.com WSJ.com Site Search WSJAsia WSJEurope WSJ Japanese Online WSJ-PRO-WSJ.com DRUGS HOUSE ILL PATIENTS PHARMACEUTICALS RIGHT TERMINALLY TO TRY UNPROVEN SB126955385469309739639045841158009767993121 Donald Trump Gottlieb, Scott Pence, Mike Walden, Greg SYND CODES_REVIEWED Health Policy </DescField><DescField fid="ipcns">ONEW OPOL </DescField></DescTPC></MetadataPT><ArchiveDoc xml:space="preserve"><Article markup="pp0" lang="en" index="field"><HandL fid="hlp"><Title fid="hl"><SectionName fid="se" index="field">Politics</SectionName><ColumnName fid="clm" index="field"></ColumnName><Headline fid="hd"><Para lang="en">House Passes Bill Giving the Terminally Ill Easier Access to Unproven Drugs; Legislation changed a version passed by Senate, seeking to address criticism by some medical groups</Para></Headline></Title><LeadPara fid="lp"><Para>The House of Representatives passed a "Right to Try" bill backed by the White House that would make unproven drugs more easily available to terminally ill patients, following changes made to address criticism of a version passed by the Senate.</Para><Para>The House voted 276-149 Wednesday in favor of the legislation written by Republican leaders of the House Energy &amp; Commerce Committee, which oversees the Food and Drug Administration. The legislation, urged by the conservative Goldwater Institute think tank, is backed by Vice President Mike Pence and was endorsed in recent speeches by President Donald Trump.</Para></LeadPara></HandL><TailParas fid="td"><Para>Proponents say the bill is necessary because desperately ill patients need help getting investigatory drugs. But critics say the measure could undermine clinical research into new prescription drugs. They also point to FDA data that show the regulator already approves more than 99% of such requests.</Para><Para>The Senate version of the legislation carried a broad definition of which patients could qualify for such unproven drugs. It would allow access by a patient "diagnosed with a life-threatening disease or condition." Critics of the legislation contend such language could potentially jeopardize much of FDA law by allowing unapproved drugs for non-terminal disease.</Para><Para>The House and Senate must reconcile their versions of the legislation before it goes to the president's desk.</Para><Para>People familiar with the events said FDA Commissioner Scott Gottlieb met in recent weeks with Rep. Greg Walden (R., Ore.), the committee chairman, and his staff, to help revise language in the bill.</Para><Para>The House bill would largely restrict such investigational drugs to patients "diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months." Also, patients could qualify if their illness could result in "significant irreversible morbidity that is likely to lead to severely premature death."</Para><Para>Rep. Walden and Rep. Michael Burgess, chairman of the committee's health subcommittee, backed the bill, acknowledging that "this is a complicated issue with passionate advocates on all sides." Rep. Walden noted that the House bill would waive liability for drug companies that supply medicine under the program. That provision, he said on the House floor Wednesday, would alleviate "manufacturers' hesitancy to participate."</Para><Para>The FDA's Dr. Gottlieb, in House committee testimony last fall, said, "Emergency requests for individual patients are usually granted immediately over the phone and nonemergency requests are generally processed within a few days," he testified. But, he told House committee members, about 10% of the time, the FDA makes "meaningful changes" to enhance patient safety, such as by altering dosages. Even so, he agreed with the estimate that over 99% of such expanded-access requests are approved.</Para><Para>Several prominent public-interest and academic-medicine doctors say the bill is an improvement of a version passed last year by the Senate, but still are skeptical that the legislation is good policy.</Para><Para>A group of more than 75 medical groups, including major ones like the American Society of Clinical Oncology, wrote to congressional leaders recently that even the House bill "is still less safe for our patients" than the FDA's system of expanded access. Four former FDA commissioners, who served under both parties, also have been critical of the legislation.</Para><Para>Harvard Medical School professor Jerry Avorn said he worries the bill could jeopardize the clinical-trial process.</Para><Para>"If it becomes hard to enroll patients in studies of new treatments because people can do an end run around the FDA and just access untested drugs directly from manufacturers, it could make it much harder to find out which new medications actually work," he said. He noted that a "very high proportion" of new drugs fail because they are "ineffective, toxic or both."</Para></TailParas><Byline fid="by" index="field">By Thomas M. Burton </Byline><Credit fid="cr" index="field"></Credit><Contact fid="ct" index="field"></Contact><Notes fid="rf" index="field"></Notes><Art fid="art" index="field"></Art><Copyright fid="cy" index="field">Copyright 2018 Dow Jones &amp; Company, Inc. All Rights Reserved. </Copyright></Article></ArchiveDoc><AdocTOC adoctype="article"><Item size="0" ref="distdoc:archive/ArchiveDoc::Article" type="arttext"></Item><Item size="0" ref="distdoc:archive/InvertText" type="invtext"></Item><Item subtype="primary" size="0" ref="https://www.wsj.com/articles/house-passes-bill-giving-the-terminally-ill-easier-access-to-unproven-drugs-1521685479" type="webpage"></Item></AdocTOC></DistDoc>

